AmideBio

AmideBio is a private, preclinical-stage biotech focused on discovering peptide drug candidates for metabolic diseases. The company operates a dual business model, combining internal therapeutic discovery with a revenue-generating service arm offering custom synthesis and catalog peptides. Its core technology integrates computational design with a proprietary manufacturing process (BioPure™) to create and produce novel peptides efficiently. Leadership includes industry veterans with significant experience in drug development, particularly in diabetes.

Integrated platform combining advanced in-silico peptide design with a proprietary synthesis and purification technology (BioPure™ process) for efficient generation of high-purity, difficult-to-manufacture peptides.

AmideBio competes in the peptide therapeutics space for metabolic disease against other biotech platforms and large pharma. Its differentiation lies in its integrated in-silico design and proprietary BioPure™ synthesis process. In the peptide services market, it competes with other CROs and manufacturers on purity, complexity, and cost.